Monte Rosa Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €102.36M +71.8% -€161.58M +10.1% -157.8% +0.88 pp N/A N/A
    (estimated) €59.58M -11.5% -€146.76M +40.5% -246.3% -0.91 pp N/A N/A
    (estimated) €67.35M +55.1% -€104.46M +4.3% -155.1% +0.76 pp €75.95M +151.4% 112.8% +0.43 pp
    (estimated) €43.41M -64.5% -€100.16M +1,979.9% -230.7% -2.3 pp €30.21M -537.5% 69.6% +0.75 pp
    (estimated) €122.15M +87.2% -€4.82M -92.3% -3.9% +0.92 pp -€6.90M -117.4% -5.7% -0.66 pp
    €65.26M +∞% -€62.74M -46.3% -96.1% -0.96 pp €39.69M -285.7% 60.8% +0.61 pp
    €0.00 +NaN% -€116.81M +29.4% N/A -€21.37M -68.9% N/A
    €0.00 +NaN% -€90.29M +45.4% N/A -€68.66M +60.3% N/A
    €0.00 +NaN% -€62.09M +99.5% N/A -€42.83M +152.4% N/A
    €0.00 +NaN% -€31.13M +349.9% N/A -€16.97M +310.7% N/A
    €0.00 -€6.92M N/A -€4.13M N/A

    Notifications